Activated PI3 kinase delta syndrome

• A trial to test the effect of leniolisib in children from 1 to 6 years of age with APDS Recruitment ended
  2022-502180-38-00 5 2024-12-16 "Activated Phosphoinositide 3-Kinase Delta Syndrome"
• A six-way relative bioavailability study comparing 10, 30, 40 and 50 mg leniolisib film coated tablets and 30 mg film coated granules with 7 … Ended
  2023-508880-61-00 3 2024-03-06 "Activated Phosphoinositide 3-Kinase Delta Syndrome"
• An open-label cocktail drug-drug interaction (DDI) clinical study to assess the effect of multiple oral dosing with leniolisib on the pharma … Ended
  2023-507134-25-00 3 2024-01-29 "Activated Phosphoinositide 3-Kinase Delta Syndrome"
• An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic fun … Ended
  2023-508519-22-00 3 2024-01-26 "Activated Phosphoinositide 3-Kinase Delta Syndrome"
• Study of Leniolisib in Pediatric Patients (Aged 4 to 11 Years) with APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Ended
  2024-515489-15-00 5 2023-09-06 "Activated Phosphoinositide 3-Kinase Delta Syndrome"

Showing 1–5 of 5 trials